TYPES OF
CANCER IMMUNOTHERAPY
Immunotherapy is a category, not a single treatment. Six distinct types work through different mechanisms, target different cancers, and require different biomarker profiles. Knowing which one is being proposed changes every downstream conversation.
What This Means for Patients
Immunotherapy is a category, not a treatment. Approaches within it work through different mechanisms, are approved for different cancers in different clinical settings, carry different side effect profiles, and sit at different stages of evidence development. Knowing which type is being discussed changes the eligibility question, the relevant response rate data, the monitoring requirements, and the financial picture.
The Six Types of Cancer Immunotherapy
Each type targets cancer through a distinct mechanism โ with separate approval histories, biomarker requirements, and evidence bases.
Checkpoint Inhibitors
PD-1 inhibitors (pembrolizumab, nivolumab), PD-L1 inhibitors (atezolizumab, durvalumab, avelumab), and CTLA-4 inhibitors (ipilimumab). Most widely approved across solid tumors. Standard immunotherapy in lung cancer, melanoma, bladder, kidney, and MSI-H colorectal cancer.
Monoclonal Antibodies & ADCs
Engineered proteins targeting specific cancer markers (HER2, EGFR, CD20). Naked mAbs flag cells for destruction or block growth signals. Antibody-drug conjugates (ADCs) deliver cytotoxic payloads directly to cancer cells โ trastuzumab deruxtecan and sacituzumab govitecan are among recent landmark approvals.
CAR-T Cell Therapy
Patient's own T-cells extracted, genetically modified to carry a cancer-targeting receptor, returned in large numbers. Multiple approved products for specific blood cancers. Solid tumor programs are actively in development.
Therapeutic Cancer Vaccines
Designed to train immune cells against specific cancer markers. Sipuleucel-T approved for prostate cancer. Personalized mRNA neoantigen vaccine programs are in advanced-phase trials with early promising results.
Cytokine Therapy
IL-2 and interferon amplify immune activity broadly rather than targeting anything specific. Among the earliest immunotherapy approaches. Still used in kidney cancer and melanoma in specific clinical contexts.
Bispecific T-Cell Engagers (BiTEs)
Engineered proteins connecting T-cells directly to cancer cells. Blinatumomab approved for certain leukemias. The category is expanding into solid tumors and additional blood cancer indications.
Who This Is Relevant For
The type matters more than the umbrella category. Blood cancer patients and solid tumor patients have access to different options. Patients with high PD-L1 expression, MSI-H status, or high TMB have the most established pathway to checkpoint inhibitors. Patients with HER2-, EGFR-, or CD20-positive tumors have established targeted antibody pathways. Neither group automatically qualifies for what the other has access to.
Benefits and Limitations
Multiple mechanism types create both opportunity and complexity.
Benefits
- Multiple targeting strategiesDifferent cancer vulnerabilities โ different patients have different access points.
- Combination approaches possibleDual checkpoint blockade and checkpoint plus chemotherapy combinations have produced the strongest clinical results.
- Expanding indicationsApproved cancer types have grown substantially in the past decade and continue to expand.
Limitations
- Category confusionKnowing it's immunotherapy without knowing which type tells you almost nothing useful about what to expect.
- Biomarker requirements varyEach type has different eligibility criteria โ HER2 testing for mAbs, MSI/TMB for checkpoint inhibitors, molecular profiling for CAR-T.
- Evidence maturity differsCheckpoint inhibitor evidence is mature; vaccine and BiTE evidence is still developing in most cancers.
How It Fits Into Advanced Cancer Treatment
The types map is the practical toolkit of the Cancer Immunotherapy field. Understanding it โ even broadly โ separates vague awareness that immunotherapy exists from the ability to ask specific, meaningful questions about what might apply to your diagnosis. Every more specific topic in the series maps to one or more entries in this list.
When to Consider This Option
When any immunotherapy is proposed: ask which category, what it specifically targets, and what the evidence looks like for your cancer type. What worked in melanoma doesn't automatically carry over to colorectal cancer. The specific type and the specific cancer together determine what expectations are grounded in evidence.
Frequently Asked Questions
Comparing Types
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Which Immunotherapy Type Could Apply to Your Diagnosis?
Matching the right type to your specific tumor biology requires molecular profiling and specialist assessment. Upload your reports and our oncology team will review which options are relevant to your case.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.